Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 6/20 | 0.42 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.42 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | USP8 | P40818 | 1/20 | 0.37 |
| ▸ | USP7 | Q93009 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13216259 | 0.86 | AR (0.44) | ARTRPV4EGLN2CYP11B1CYP11B2 | |
| SCHEMBL2693449 | 0.84 | AR (0.47) | ARTRPV4CYP11B1CYP11B2TSHR | |
| SCHEMBL13199476 | 0.82 | TSHR (0.43) | ARTRPV4EGLN2CYP11B1CYP11B2 | |
| SCHEMBL6364089 | 0.82 | TRPV4 (0.42) | ARTRPV4CYP11B1CYP11B2TSHR | |
| SCHEMBL24075906 | 0.78 | AR (0.41) | ARTRPV4EGLN2CYP11B2TSHR | |
| SCHEMBL31673035 | 0.78 | ESR1 (0.41) | ARTRPV4CYP11B1CYP11B2TSHR | |
| SCHEMBL20954185 | 0.78 | TRPV4 (0.39) | ARTRPV4CYP11B1CYP11B2TSHR | |
| SCHEMBL31171401 | 0.78 | AR (0.41) | ARTRPV4EGLN2CYP11B2TSHR | |
| SCHEMBL152425 | 0.78 | AR (0.40) | ARTRPV4EGLN2CYP11B1CYP11B2 | |
| SCHEMBL152108 | 0.78 | EGLN2 (0.43) | ARTRPV4EGLN2CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577231-B2 | Androgen receptor PROTACS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2026-03-17 | — | — | US | disclosed |
| US-20260001865-A1 | ANDROGEN RECEPTOR PROTACS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2026-01-01 | — | — | US | disclosed |
| WO-2025061906-A1 | ANDROGEN RECEPTOR PROTACS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-03-27 | — | — | WO | disclosed |
| US-20250100981-A1 | Cis-substituted 5-(hydroxymethyl)morpholine-2-carboxamides as agonists of SSTR4 | BOEHRINGER INGELHEIM INT (DE) | 2025-03-27 | — | — | US | disclosed |
| WO-2025049939-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATOR BASED RADIOPHARMACEUTICALS FOR IMAGING ANDROGEN RECEPTOR | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2025-03-06 | — | — | WO | disclosed |
| WO-2025027049-A1 | (2S,5R)-5-(HYDROXYMETHYL)MORPHOLINE-2-CARBOXAMIDES AS AGONISTS OF SSTR4 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-02-06 | — | — | WO | disclosed |
| WO-2024211969-A1 | PPARG MODULATORS | Setonix Pharmaceuticals Pty Ltd (AU) | 2024-10-17 | — | — | WO | disclosed |
| US-11518764-B2 | Substituted heteroaryls as inhibitors of the BCL6 BTB domain protein-protein interaction | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-12-06 | — | — | US | disclosed |
| US-11358931-B2 | Selective androgen receptor modulators (SARMs) and uses thereof | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2022-06-14 | — | — | US | disclosed |
| US-20200361866-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2020-11-19 | — | — | US | disclosed |
| US-20100256129-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF | LIGAND PHARMACEUTICALS INCORPORATED | 2010-10-07 | — | — | US | disclosed |
| EP-2222636-A2 | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF | Ligand Pharmaceuticals Inc. (US) | 2010-09-01 | — | — | EP | disclosed |
| WO-2009082437-A9 | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2010-08-12 | — | — | WO | disclosed |
| EP-2176220-A2 | PYRROLIDIN-2-ONE DERIVATIVES AS ANDROGEN RECEPTOR MODULATOR | Takeda Pharmaceutical Company Limited (JP) | 2010-04-21 | — | — | EP | disclosed |
| US-20100087506-A1 | CYCLIC AMINE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-2098507-A1 | CYCLIC AMINE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-09-09 | — | — | EP | disclosed |
| WO-2009082437-A2 | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009020234-A2 | PYRROLIDIN-2 -ONE DERIVATIVES AS ANDROGEN RECEPTOR MODULATOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-12 | — | — | WO | disclosed |
| US-20090042967-A1 | Cyclic amine compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-12 | — | — | US | disclosed |
| US-20050054733-A1 | Difluoroalkylaromatics | LANXESS DEUTSCHLAND GMBH (DE) | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11518764-B2 | Substituted heteroaryls as inhibitors of the BCL6 BTB domain protein-protein interaction | BCL6, BCL6B, BCL3 | AR 1375/4885TRPV4 4510/4885EGLN2 1011/4885 |
| US-20200361866-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF | AR, NR5A1, SHBG | AR 1/4885TRPV4 1287/4885EGLN2 2332/4885 |
| US-20100256129-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF | AR, NR5A1, SHBG | AR 1/4885TRPV4 1604/4885EGLN2 1545/4885 |
| US-11358931-B2 | Selective androgen receptor modulators (SARMs) and uses thereof | AR, NR5A1, SHBG | AR 1/4885TRPV4 1424/4885EGLN2 2001/4885 |
| US-20260001865-A1 | ANDROGEN RECEPTOR PROTACS | AR, CRBN, PSMA3 | AR 1/4885TRPV4 4281/4885EGLN2 2213/4885 |
| US-12577231-B2 | Androgen receptor PROTACS | AR, CRBN, PSMA3 | AR 1/4885TRPV4 4281/4885EGLN2 2213/4885 |
| US-20090042967-A1 | Cyclic amine compounds | SHBG, FSHR, ACP3 | AR 4/4885TRPV4 3417/4885EGLN2 476/4885 |
| US-20050054733-A1 | Difluoroalkylaromatics | NQO1, TYR, FLI1 | AR 2057/4885TRPV4 3436/4885EGLN2 2097/4885 |
| US-20250100981-A1 | Cis-substituted 5-(hydroxymethyl)morpholine-2-carboxamides as agonists of SSTR4 | SSTR4, SSTR5, SSTR2 | AR 428/4885TRPV4 250/4885EGLN2 1493/4885 |
| US-20100087506-A1 | CYCLIC AMINE COMPOUND | AR, FSHR, NR5A1 | AR 1/4885TRPV4 1687/4885EGLN2 545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.